ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.
| Website | http://www.projenx.com |
| Employees | 9 (6 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology Research |
| Keywords | Biotechnology, Neurodegenerative Diseases, Als Research, Amyotrophic Lateral Sclerosis, Clinical Stage, Targeted Therapies, Drug Development, Novel Treatments, Clinical Trials, Therapeutics, Biomedical Research, Advanced Therapies, Pharmaceutical, Neurology, Life Sciences, New Medicines, Scientific Research, Molecular Medicine, Health Technology |
| Competitors | Atlassian, Smartsheet, monday.com, Asana, ClickUp, Wrike, Teamwork, ProjectManager, Tierney Performance, Trello +45 more (view full list) |
Looking for a particular ProJenX employee's phone or email?
ProJenX Questions
Stan Abel is the President and Chief Executive Officer of ProJenX.
6 people are employed at ProJenX.
ProJenX is based in New York, New York.
Top ProJenX Employees
-
Stan Abel
President and Chief Executive Officer at ProJenX
New York, NY, US24 -
Erin Fleming
Chief Operating Officer at ProJenX
New York, NY, US35+ -
Ingela Danielsson
Medical Advisor and Medical Monitor Late Phase at ProJenX
San Antonio, TX, US55+ -
21
-
Margot Shanahan
Community Engagement, Lead at ProJenX
New York, United States31 -
Maike Roth
Project Manager at ProJenX
San Francisco, CA, US22
Related Companies
